We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

T:CRYPTOCAPMarket Cap T, $ Analysis

Data as of 2026-03-15 - not real-time

$27.72

Latest Price

4/10Risk

Risk Level: Medium

Executive Summary

AT&T’s stock is trading at $27.72, which sits just above its 20‑day SMA but remains below the 50‑day SMA, indicating a modest short‑term upside bias. The 200‑day SMA is marginally higher, suggesting the longer‑term trend is still neutral. Momentum measured by the RSI hovers around the mid‑50s, confirming the absence of extreme overbought or oversold conditions. However, the MACD line sits beneath its signal line and the histogram is negative, a bearish divergence that often precedes a corrective pullback. The price is positioned near the identified support level of $26.73 and below the resistance at $29.07, leaving limited upside before encountering resistance. Volume has been stable, and the beta, whether using the computed 0.09 figure or the exchange‑reported 0.58, points to lower volatility than the market. The 30‑day historical volatility of roughly 28 % adds a moderate swing component, but overall price swings remain contained.
Fundamentally, the company trades at a trailing PE of about 9, well under the telecom industry average of 18, and its price‑to‑book sits at 1.76, implying a modest discount to net assets. The dividend yield of 4 % is attractive, and a payout ratio near 27 % is comfortably supported by free cash flow exceeding $12 bn, indicating sustainable payouts. Nevertheless, the DCF fair value of roughly $8.2 is far below the current market price, flagging a substantial overvaluation on intrinsic terms. A debt‑to‑equity ratio above 120 % reflects a heavily leveraged balance sheet, though operating cash flow remains robust. Given the blend of defensive cash generation, high yield, and an over‑priced market valuation, the stock is best viewed as a value‑oriented play with limited upside potential.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bearish MACD divergence
  • Price near support with limited upside
  • Stable volume

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Low PE relative to industry
  • Strong free cash flow supporting dividend
  • Attractive 4% dividend yield

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • DCF fair value far below price indicating overvaluation
  • High leverage may constrain future growth
  • Sustainable dividend but limited upside

Key Metrics & Analysis

Financial Health

Revenue Growth3.60%
Profit Margin17.47%
P/E Ratio9.1
ROE18.80%
ROA4.07%
Debt/Equity124.18
P/B Ratio1.8
Op. Cash Flow$40.3B
Free Cash Flow$12.6B
Industry P/E17.8

Technical Analysis

TrendNeutral
RSI52.1
Support$26.73
Resistance$29.07
MA 20$28.10
MA 50$26.26
MA 200$26.85
MACDBearish
VolumeStable
Fear & Greed Index72.88

Valuation

Fair Value$8.24
Target Price$29.96
Upside/Downside8.07%
GradeOvervalued
TypeValue
Dividend Yield4.00%

Risk Assessment

Beta0.09
Volatility27.91%
Sector RiskLow
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.